Rabeprazole

Rabeprazole (CAS 117976-89-3 ), also referenced in development literature as E-3810 and LY307640, is a proton pump inhibitor (PPI) active pharmaceutical ingredient used in the treatment of acid-related gastrointestinal disorders.

It functions by irreversibly suppressing gastric acid secretion, making it a target API for finished dosage form manufacturers and generic drug developers worldwide. Rabeprazole is the active ingredient in delayed-release oral solid dosage forms.

These are primarily enteric-coated tablets and capsules formulated to treat conditions such as gastroesophageal reflux disease, peptic ulcers, and Zollinger-Ellison syndrome. Generic pharmaceutical manufacturers source the API to produce bioequivalent formulations.

These formulations are intended for regulated markets in the US, EU, and Asia-Pacific. Contract development and manufacturing organizations (CDMOs) also procure it for combination therapies, including H. pylori eradication regimens paired with antibiotics.

Formulators working on pediatric or modified-release formats may source it as an intermediate for specialized dosage development. Rabeprazole is supplied as a white to off-white crystalline powder.

The sodium salt form (Rabeprazole Sodium) is the predominant commercial grade. Material is available to USP , BP , and Ph. Eur. pharmacopoeial standards, supporting regulatory submissions across major markets.

Packaging is typically offered under inert atmosphere or moisture-controlled conditions to maintain API integrity during storage and transit. This ensures the chemical stability required for long-term pharmaceutical manufacturing.

Contact us for supply of Rabeprazole